- 51 -
- 52 -
参考文献
1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976; 194:
23-28.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA. Systemic spread is an early step in breast cancer.
Cancer Cell 2008; 13: 58-68.
4. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N. Engl. J. Med. 2006; 355: 1 253-1261.
5. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
6. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, Cai X, Fox JG,
Goldenring JR, Wang TC. Gastric cancer originating from bone marrow-derived cells.
Science 2004; 306: 1568-1571.
7. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
8. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
9. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, Shelton AA, Parmiani G, Castelli C, Clarke MF. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA
- 53 - 2007; 104: 10158-10163.
10. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H.
Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem. Biophys. Res. Commun. 2006; 351: 820-824.
11. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251.
12. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB.
Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63:
5821-5828.
13. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells.
Nature 2004; 432: 396-401.
14. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. USA 2004; 101:
781-786.
15. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG,
Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer. Inst. 2008; 100:
672-679.
16. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
17. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu
- 54 -
JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006; 5: 67.
18. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
19. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm.
Science 2009; 324: 1670-1673.
20. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008; 8: 755-768.
21. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the
cells-of-origin of intestinal cancer. Nature 2009; 457: 608-611.
22. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009; 457: 603-607.
23. Yajima T, Ochiai H, Uchiyama T, Takano N, Shibahara T, Azuma T. Resistance to cytotoxic chemotherapy-induced apoptosis in side population cells of human oral squamous cell carcinoma cell line Ho-1-N-1. Int. J. Oncol. 2009; 35: 273-280.
24. Pellegrini G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bondanza S, Ponzin D, McKeon F, De Luca M. p63 identifies keratinocyte stem cells. Proc. Natl. Acad.
Sci. USA 2001; 98: 3156-3161.
25. McKeon F. p63 and the epithelial stem cell: more than status quo? Genes Dev. 2004;
18: 465-469.
26. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D, McKeon F. p63, a p53 Homolog at 3q-27-29, encodes multiple products with
- 55 -
transactivating, death-inducing, and dominant-negative activities. Molecular Cell 1998; 2: 305-316.
27. Augustin M, Bamberger C, Paul D, Schmale H. Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm. Genome 1998; 9: 899-902.
28. Trink B, Okami, Wu L, Sriuranpong V, Jen J, Sidransky D. D. A new human p53 homologue. Nat. Med. 1998; 4: 747-748.
29. Ikawa S, Nakagawara A, Ikawa Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 1999; 6: 1154-1161.
30. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000; 19: 3439-3444.
31. Jost CA, Marin MC, Kaelin WG. p73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389: 191-194.
32. Hagiwara K, McMenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res. 1999; 59: 4165-4169.
33. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005; 19: 2122-2137.
34. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidransky D. AIS is an oncogene amplified in squamous cell carcinoma. Proc.
Natl. Acad. Sci. USA 2000; 97: 5462-5467.
35. Ratovitski EA, Patturajan M, Hibi K, Trink B, Yamaguchi K, Sidransky D. p53
- 56 -
associates with and targets ΔNp63 into a protein degradation pathway. Proc. Natl.
Acad. Sci. USA 2001; 98: 1817-1822.
36. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratovitski E, Sidransky D. ΔNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1: 369-379.
37. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient ΔTA-p73 acts as anoncogene. Cancer Res. 2002; 62: 3598-3602.
38. Wu G, Nomoto S, Hoque MO, Dracheva T, Osada M, Lee CC, Dong SM, Guo Z, Benoit N, Cohen Y, Rechthand P, Califano J, Moon CS, Ratovitski E, Jen J, Sidransky D, Trink B. ΔNp63α and TAp63α regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 2003; 63:
2351-2357.
39. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat. Rev. Mol.
Cell Biol. 2000; 1: 199-207.
40. Mills AA. p63: oncogene or tumor suppressor? Curr. Opin. Genet. Dev. 2006; 16:
38-44.
41. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. p63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev. 2004; 18: 126-131.
42. Koster MI, Roop DR. The role of p63 in development and differentiation of the epidermis. J. Dermatol. Sci. 2004; 34: 3-9.
43. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63α and ΔN-p63 in benign and malignant oral epithelial lesions. Int. J. Cancer 2000; 87:
368-372.
44. Pruneri G, Pignataro L, Manzotti M, Carboni N, Ronchetti D, Neri A, Cesana BM,
- 57 -
Viale G. p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Lab. Invest. 2002; 82: 1327-1334.
45. Glickman JN, Yang A, Shahsafaei A, Mckeon F, Odze RD. Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum. Pathol. 2001; 32: 1157-1165.
46. Geddert H, Kiel S, Heep HJ, Gabbert HE, Sarbia M. The role of p63 and ΔNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum.
Pathol. 2003; 34: 850-856.
47. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis.
Cancer Res. 2003; 63: 7113-7121.
48. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg. Oral Med. Oral Pathol. 1978;
46: 518-539.
49. Burkhardt A. Premalignant changes in the mouth mucosa. Proposals for
nomenclature by an international expert commission. Pathologe. 1985; 6: 126-132.
50. Gale N, Pilch BZ, Sindramsky D, EI Nagger A, Westra W, Califano W, Johnson N, MacDonald DG. Epithelial precursor lesions. In: Barnes L, Eveson J, Reichart P, Sidransky D, eds. World Health Organization classification of tumors. Pathology and genetics of head and neck tumors. Lyon: Iarc Press, 2005; 177-179.
51. Wahi PN, Cohen B, Luthra UK et al. Histological consideration. In: Wahi PN, Cohen B, Luthra UK et al., eds. Histological typing of oral and orpharyngeal tumors.
- 58 -
Geneva, Switzerland: World Health Organization, 1977; 15-19.
52. Yamamoto E, Miyakawa A, Kohama G. Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg. 1984; 6: 938-947.
53. Fuchs E, Segre JA. Stem cells: a new lease on life. Cell 2000; 100: 143-155.
54. Watt FM, Hogan BL. Out of Eden: stem cells and their niches. Science 2000; 287:
1427-1430.
55. Lehrer MS, Sun TT, Lavker RM. Strategies of epithelial repair: modulation of stem cell and transit amplifying cell proliferation. J. Cell Sci. 1998; 111: 2867-2875.
56. Morris RJ, Potten CS. Slowly cycling (label-retaining) epidermal cells behave like clonogenic stem cells in vitro. Cell Prolif. 1994; 27: 279-289.
57. Morris RJ, Potten CS. Highly persistent label-retaining cells in the hair follicles of mice and their fate following induction of anagen. J. Invest. Dermatol. 1999; 112:
470-475.
58. Taylor G, Lehrer MS, Jensen PJ, Sun TT, Lavker RM. Involvement of follicular stem cells in forming not only the follicle but also the epidermis. Cell 2000; 102: 451-461.
59. Cotsarelis G, Cheng SZ, Dong G, Sun TT, Lavker RM. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate:
implications on epithelial stem cells. Cell 1989; 57: 201-209.
60. Chen YK, Hsue SS, Lin LM. Expression of p63 protein and mRNA in oral epithelial dysplasia. J. Oral Pathol. Med. 2005; 34: 232-239.
61. Chen YK, Huse SS, Lin LM. Immunohistochemical demonstration of p63 in
DMBA-induced hamster buccal pouch squamous cell carcinogenesis. Oral Diseases 2003; 9: 235-240.
62. Lo Muzio L, Santarelli A, Caltabiano R, Rubini C, Pieramici T, Trevisiol L, Carinci F,
- 59 -
Leonardi R, De Lillo A, Lanzafame S, Bufo P, Piattelli A. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum.
Pathol. 2005; 36: 187-194.
63. Borba M, Cernea C, Dias F, Faria P, Bacchi C, Brandão L, Costa A. Expression Profile of p63 in 127 Patients with Laryngeal Squamous Cell Carcinoma. ORL J Otorhinolaryngol. Relat. Spec. 2010; 72: 319-324.
64. Moergel M, Abt E, Stockinger M, Kunkel M. Overexpression of p63 is associated with radiation resistance and prognosis in oral squamous cell carcinoma. Oral Oncol.
2010; 46: 667-671.
65. Oliveira LR, Ribeiro-Silva A, Costa JP, Simões AL, Matteo MA, Zucoloto S.
Prognostic factors and survival analysis in a sample of oral squamous cell carcinoma patients. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2008; 106:
685-695.
66. Foschini MP, Gaiba A, Cocchi R, Pennesi MG, Gatto MR, Frezza GP, Pession A.
Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch. 2004; 444: 332-339.
67. Candi E, Rufini A, Terrinoni A, Dinsdale D, Ranalli M, Paradisi A, De Laurenzi V, Spagnoli LG, Catani MV, Ramadan S, Knight RA, Melino G. Differential roles of p63 isoforms in epidermal development: selective genetic complementation in p63 null mice. Cell Death Differ. 2006; 13: 1037-1047.
68. Romano RA, Birkaya B, Sinha SJ Invest Dermatol. A functional enhancer of
keratin14 is a direct transcriptional target of ΔNp63. J. Invest. Dermatol. 2007; 127:
1175-1186.
69. Byrne C, Tainsky M, Fuchs E. Programming gene expression in developing
- 60 - epidermis. Development 1994; 120: 2369-2383.
70. Romano RA, Ortt K, Birkaya B, Smalley K, Sinha S. An active role of the ΔN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One 2009; 4: e5623.
71. Chiang CT, Chu WK, Chow SE, Chen JK. Overexpression of ΔNp63 in a human nasopharyngeal carcinoma cell line downregulates CKIs and enhances cell proliferation. J. Cell Physiol. 2009; 219: 117-122.
72. Beretta C, Chiarelli A, Testoni B, Mantovani R, Guerrini L. Regulation of the cyclin-dependent kinase inhibitor p57Kip2 expression by p63. Cell Cycle 2005; 4:
1625-1631.
73. Westfall MD, Mays DJ, Sniezek JC, Pietenpol JA. The ΔNp63α phosphoprotein binds the p21 and 14-3-3σ promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol. Cell Biol.
2003; 23: 2264-2276.
74. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA.
The epithelial-mesenchymal transition generates cells with properties of stem cells.
Cell 2008; 133: 704-715.
75. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL.
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009; 69: 2887-2895.
76. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev.
Cancer 2002; 2: 442-454.